CGRP mAb Subcutaneous denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issued a Duplicate-Therapy Denial for Your CGRP Monoclonal Antibody

UnitedHealthcare's duplicate-therapy denial indicates that UHC's claims system identified another active CGRP monoclonal antibody claim or authorization on your account — either a currently approved agent, a recently dispensed supply that has not yet expired per the plan's records, or a concurrent authorization for a different agent in the same pharmacologic class. UHC's clinical policies for this drug class generally do not permit simultaneous coverage of two CGRP antibodies, and the automated review flags any overlap.

## Why This Denial Is Appealable

This denial is frequently overturned because the "duplicate" is often a technical overlap rather than a genuine concurrent use: an authorization that was approved but the drug was never dispensed; a prior agent that was discontinued but the PA is still showing as active in UHC's system; or a coverage transition during which two records briefly co-exist. Each CGRP monoclonal antibody also has distinct clinical characteristics, and UHC's own coverage policy recognizes circumstances permitting a switch — including documented non-response, tolerability failure, or a formulary change that removed the previously covered agent.

## Your Federal Appeal Rights

• ERISA §503 applies to self-funded employer plans and requires a full-and-fair review with a decision on standard appeals within 60 days of submission.
• ACA §2719 gives you the right to an Independent External Review after final internal denial; the external-review window is generally approximately four months.
• Expedited internal review (decision within 72 hours) is available when the standard timeline would seriously jeopardize your health.
• For fully insured UHC plans, your state insurance department's external-review process may run concurrently or alternatively — check the denial letter for state-specific instructions.

## Documentation to Gather

• Prior CGRP agent authorization and dispensing history: request a PA history printout from UHC and a dispensing history from your pharmacy; confirm whether the prior agent was actually dispensed and when the supply was exhausted or discontinued.
• Discontinuation documentation: a prescriber note or pharmacy record confirming the prior agent was stopped, with the date and reason (non-response, adverse effect, formulary removal, patient preference).
• Clinical rationale for current agent: a prescriber letter explaining why this agent is being initiated now, why it is not concurrent with the prior agent, and how it differs clinically if a switch.
• UHC's duplicate-therapy or CGRP coverage policy: download the current UnitedHealthcare medical policy for CGRP antagonists from uhcprovider.com or myuhc.com; your appeal should cite the switching criteria verbatim.

## Criteria-Mapping Structure

| UHC Policy Requirement | Supporting Evidence | |---|---| | No concurrent active CGRP authorization | PA history showing prior auth closed or expired; pharmacy record showing last dispense date | | Clinical basis for agent change (if switching) | Prescriber letter documenting failure/intolerance of prior agent with dates | | Current agent is medically necessary | Prescriber medical-necessity letter addressing UHC's criteria |

Verify the exact criteria and switching requirements by reading UHC's current published CGRP medical coverage policy and the FDA-approved prescribing label for the requested agent before filing your appeal.